Eli Lilly

Ozempic syringe pen and measuring tape on blue background

Biotech

Novo plots ph. 3 trials for next-gen obesity asset amycretin

The Danish pharma is moving forward with both subcutaneous and oral versions of amycretin, a GLP-1 and amylin receptor agonist.

Gabrielle Masson Jun 13, 2025 10:35am

Anatomical model of human arm and torso showing muscle

Eli Lilly inks $650M Juvena pact to find muscle-boosting drugs

Jun 11, 2025 7:30am

Antares and Rho Ophiuchi cloud complex in the Sagittarius constellation

Scorpion spinout Antares raises $177M for preclinical portfolio

Jun 10, 2025 10:07am

photo of a pair of binoculars perched on a rock aimed at the rising sun

Are Lilly, Novartis eyeing the PD-1xVEGF field? Execs weigh in

Jun 4, 2025 1:00pm

Graphic images of white and black puzzle pieces connecting seamlessly

Eli Lilly taps Camurus' tech to advance long-acting obesity meds

Jun 3, 2025 5:04pm

Illustration connected puzzle pieces with the acronym MA

Lilly lands next-gen pain asset in $1B SiteOne acquisition

May 27, 2025 11:30am